Let’s pair groundbreaking science with relentless drive.
Let’s get this done.

Saqib Islam was appointed Chief Executive Officer of SpringWorks Therapeutics in 2018. He was a founding member of the company’s executive team since its launch in 2017 and previously served as Chief Financial Officer and Chief Business Officer of the company. Prior to joining SpringWorks, Saqib was Chief Business Officer at Moderna Therapeutics, where he oversaw critical aspects of the company’s growth, including global strategic planning, corporate development and business development. Prior to Moderna, Saqib served as Executive Vice President, Chief Strategy and Portfolio Officer at Alexion Pharmaceuticals, executing the company’s corporate growth strategies and contributing to its assessment and management of global operations. Saqib has over 25 years of international business management experience and an extensive background in the healthcare banking sector, having held managing director positions in the investment banking divisions of Morgan Stanley and Credit Suisse Securities. He currently serves on the Board of Directors of Passage Bio (where he also serves as a member of its Audit Committee) and ARS Pharmaceuticals (where he also serves as a member of its Compensation Committee). Saqib received his bachelor’s degree from McGill University, graduating as a Faculty and University Scholar, and a J.D. from Columbia Law School, where he was a Harlan Fiske Stone Scholar.

Dr. Badreddin Edris joined SpringWorks Therapeutics in 2018. He has approximately 15 years of experience in private and public equity investing, company formation and operations, corporate and business development, and strategic and product planning in the biotechnology industry. Previously, Badreddin was an investment and operating professional on the private equity team at OrbiMed, where he was involved in deal sourcing, evaluation and execution, as well as post-investment strategic and operational support for biotechnology companies across a range of therapeutic areas and stages of development. Badreddin also co-founded and held operating roles at two OrbiMed portfolio companies, Silverback Therapeutics (where he was Chief Business Officer) and Edgewise Therapeutics (where he was Chief Operating Officer and currently serves on the Board of Directors). Before OrbiMed, Badreddin was a management consultant at Bain & Company, where he collaborated with global pharmaceutical and biotechnology companies on a range of strategic and operational projects. Badreddin received his Ph.D. in genetics from Stanford University, where he was an NSF Research Fellow.

Dr. James (Jim) Cassidy joined SpringWorks in 2021. He has over 30 years of experience in oncology as an academic physician-scientist and a drug development leader in both biotechnology and pharmaceutical companies, with experience spanning from early-stage research to translational and clinical development to post-marketing medical affairs strategy and lifecycle management. Previously, Jim was Vice President of Oncology Strategic Program Direction at Regeneron Pharmaceuticals. Prior to Regeneron, Jim was Corporate Vice President of Translational Development at Celgene, where he oversaw translational science efforts for the company’s entire portfolio of programs addressing both hematological malignancies and solid tumors. Before Celgene, he was Vice President of Oncology at Bristol-Myers Squibb, where he was responsible for all oncology assets from development candidate nomination through clinical proof-of-concept studies, including biomarkers and translational research, and was closely involved with late-stage development, commercial, and business development efforts as well. Prior to Bristol-Myers Squibb, Jim held several roles of increasing responsibility at Hoffmann La-Roche, including Global Head of Translational Research for Oncology and Acting Head of the Oncology Therapy Area. Before joining Roche, he had been a leading academic physician-scientist, most recently having served as Professor of Oncology, Head of the Department of Cancer Research and Head of the Division of Cancer Sciences and Molecular Pathology at the University of Glasgow in Scotland. Jim received his medical degree and doctorate from the University of Glasgow.

Dr. Tai-An Lin joined SpringWorks in 2023. He has more than 25 years of biotechnology and global pharmaceutical experience in advancing drug discovery programs from target identification to early clinical trials across the therapeutic areas of oncology, immuno-oncology, and immunology. Previously, Tai-An was Senior Vice President of Translational Science and Discovery Biology of Black Diamond Therapeutics. Before Black Diamond, Tai-An was a Director of Immuno-Oncology Translational Innovation Platform and Experimental Medicine at Merck KGaA/EMD Serono leading translational biomarker research team and IO precision medicine efforts. Prior to EMD Serono, Tai-An had extensive experience in leading multidisciplinary drug discovery teams and biology groups at global pharmaceutical companies including Bristol-Myers Squibb, Roche, and Janssen Pharmaceuticals; key accomplishments included early discovery efforts for several kinase inhibitors including dasatinib, and leadership of BMS’s linrodostat and Roche’s RG7185 projects. 

Frank Perier joined SpringWorks Therapeutics in 2019. He has more than 25 years of experience leading finance organizations in the pharmaceutical industry. Previously, Frank was the Chief Financial Officer at Forest Laboratories, Inc. for 10 years before the company’s acquisition by Actavis. Before joining Forest, Frank was with Bristol-Myers Squibb for approximately nine years, where he worked in corporate and operations finance capacities of increasing responsibilities, including Vice President of Finance and Operations Planning-Americas Medicines Group, the company’s largest business unit at that time. Before joining Bristol-Myers Squibb, he was an accounting and auditing partner at Deloitte, where he worked for about 15 years. Frank was a member of the Board of Directors of Concordia International, Inc., a specialty pharmaceutical company, until September 2018 where he served on the Audit and the Human Resources and Compensation Committees of the Company. Frank received a B.S. in accountancy from Villanova University and an MBA from the Stern School of Business, New York University. He is a Certified Public Accountant (inactive) and a member of the New Jersey Society of Certified Public Accountants and the American Institute of Certified Public Accountants.

Bhavesh Ashar joined SpringWorks Therapeutics in 2021. He has more than 20 years of global pharmaceutical and biotechnology experience, including significant experience in oncology. Previously, Bhavesh was Senior Vice President, General Manager of U.S. Oncology at Bayer Healthcare, where he served as Business Unit Head for the U.S. Oncology franchise and was responsible for a broad portfolio in prostate, liver, colorectal, GIST, hematologic and tumor-agnostic biomarker-driven cancers. Prior to joining Bayer in 2017, Bhavesh held roles of increasing responsibility at Sanofi Genzyme over a 15-year tenure, including Vice President, General Manager of U.S. Oncology and Vice President, Global Head of Transplant. Prior to Sanofi Genzyme, Bhavesh was a consultant with McKinsey & Company, where he served clients in the biopharmaceutical space. Bhavesh received a B.S. in mathematics from the Imperial College in London and an MBA from the University of Chicago.

Daniel Pichl joined SpringWorks Therapeutics in 2020. He has more than 15 years of experience as an accomplished human resource professional. Previously, Daniel was at Siemens Healthineers, USA where he was Senior Vice President, Head of Human Resources and Global HR Business Partner for the Ultrasound division. At Siemens, he had global responsibility for People Strategy, Employee Relations, Compensation & Benefits, Talent Acquisition, Talent & Performance Management, Leadership Development, and Learning. Prior to this role, he served as Vice President, Head of People & Leadership for the Americas region, and before that, he held positions of increasing responsibility at Siemens AG, Germany. Daniel earned a Master of International Business degree from Macquarie University in Sydney, Australia, and a Master of Psychology degree from Ludwig-Maximilians-University in Munich, Germany.

Dr. Kristin Patterson joined SpringWorks Therapeutics in 2018.  She has more than 20 years of pharmaceutical and biotechnology experience with expertise in CMC development, supply chain logistics and commercial manufacture.  Kristin built the CMC function at SpringWorks and continues to play an integral role in defining the manufacturing and CMC regulatory strategy for all assets in development. Previously, Kristin spent 2 years at Mycovia Pharmaceuticals where she led drug product development and manufacturing for multiple anti-fungal assets and 1 year at NephroGenex where she led CMC and CMC regulatory functions.  Kristin spent the first 14 years of her career at GlaxoSmithKline, where she led global, cross-functional teams and provided CMC leadership to development programs from lead optimization to product registration and launch.  During her time at GlaxoSmithKline, she contributed to multiple NDAs and global regulatory filings.  In addition, she spent three years on the Emerging Markets R&D team, which provided a unique opportunity to build her understanding of the development, manufacturing and regulatory requirements needed to expand into these additional geographies. Kristin received her B.S. in Chemistry from the University of Illinois and her Ph.D. in Chemistry from Stanford University.

Joe Zimmerman joined SpringWorks in 2022. He has nearly 30 years of experience in the pharmaceutical industry in leadership roles of increasing responsibility, including corporate compliance, privacy, government affairs, leadership development, training, management, and sales. Prior to SpringWorks, Joe served as Vice President, Chief Compliance & Privacy Officer and Head of U.S. Government Affairs at Ferring Pharmaceuticals, Inc. Previously, he served as Senior Vice President and Chief Compliance Officer for Actavis (merged with Allergan now AbbVie) and Forest Laboratories (acquired by Actavis). Prior to these roles, he also held the position of Global Chief Compliance Officer for Forest where he established the corporate function and managed the teams providing compliance support for numerous new product approvals, branded drug launches, and various M&A activity.  He received a B.S. in Biology from Bradley University.